Q3 Revenue Jumps 65% to $21.6M, Full-Year Guidance Raised to $78-80M
CARL sits 73% above its 52-week low of $8.5.
Summary
Carlsmed delivered Q3 2026 revenue of $21.6 million, up 65% from $13.1 million a year ago, and lifted full-year 2026 guidance to $78-80 million from the prior $74-78 million range — over 56% growth at the midpoint. Gross margin improved to 77.3% from 75.9%, and adjusted EBITDA loss narrowed to $7.3 million from $8.2 million. The bottom line is still red: net loss widened to $12.2 million from $8.5 million, with operating expenses up to $29.4 million including $2.8 million of executive transition and legal settlement costs. The quarter also brought new inpatient CMS reimbursement for the aprevo lumbar procedure effective October 1 and an October launch of the aprevo Lumbar Bi-lateral Posterior System, which the company estimates addresses roughly 30,000 U.S. lumbar fusion procedures annually. Cash, restricted cash, short-term investments and marketable securities totaled $80.3 million at quarter end, against a $250 million shelf registered in August that remains available for future raises.
At the time of this announcement, CARL was trading at $14.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $401.6M. The 52-week trading range was $8.50 to $17.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.